ACOG Suit Petitions the FDA to Remove Burdensome Barriers to Reproductive Care During COVID-19
May 27, 2020
Washington, DC – The American College of Obstetricians and Gynecologists (ACOG) took another step toward achieving equitable access to care for patients during the COVID-19 pandemic by asking a federal court to require the U.S. Food and Drug Administration (FDA) to suspend a harmful FDA restriction on mifepristone. Joining ACOG as plaintiffs in today’s lawsuit are the Council of University Chairs of Obstetrics and Gynecology, the New York Academy of Family Physicians, and SisterSong Women of Color Reproductive Justice Collective.
Mifepristone is an evidence-based treatment prescribed for management of early pregnancy loss as well as induced abortion. Although mifepristone has long been proven to be safe and effective when prescribed through telemedicine and can be safely taken in the comfort of a patient’s home, outdated FDA restrictions require mifepristone to be dispensed in a hospital, clinic, or medical office.
Facebook
Google+
Twitter
LinkedIn